SCHEMBL5881256

SCHEMBL5881256

C#CCCCO[Si](C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.31
MAOB P27338 2/20 0.31
CA12 O43570 2/20 0.31
CA9 Q16790 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7111604 0.93 MAOA (0.33) MAOAMAOB
SCHEMBL7117424 0.91 MAPT (0.35) MAOAMAOB
SCHEMBL2063931 0.84
SCHEMBL1578618 0.79 DUT (0.37)
SCHEMBL7882674 0.76
SCHEMBL662237 0.76 DUT (0.36) MAOAMAOB
SCHEMBL7052818 0.75 TSHR (0.42)
SCHEMBL12598353 0.75
SCHEMBL23727498 0.74 DUT (0.35)
SCHEMBL5244051 0.74 MAOA (0.30) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0800525-B1 PROCESS FOR PREPARING TRIMETHYLSILYLOXY FUNCTIONALIZED ALKYLLITHIUM COMPOUNDS FMC CORP (US) 2003-04-09 EP claimed
US-6989450-B2 Synthesis of epothilones and related analogs THE UNIVERSITY OF MISSISSIPPI (US) 2006-01-24 US disclosed
EP-1414384-A4 SYNTHESIS OF EPOTHILONES AND RELATES ANALOGS UNIV MISSISSIPPI (US) 2005-07-27 EP disclosed
EP-1414384-A2 SYNTHESIS OF EPOTHILONES AND RELATES ANALOGS The University of Mississippi (US) 2004-05-06 EP disclosed
US-20020091269-A1 Synthesis of epothilones and related analogs TAPESTRY PHARMACEUTICALS, INC. 2002-07-11 US disclosed
WO-2002030356-A2 SYNTHESIS OF EPOTHILONES AND RELATES ANALOGS THE UNIVERSITY OF MISSISSIPI (US) 2002-04-18 WO disclosed
WO-1999064048-A9 INHIBITORS OF HIV REVERSE TRANSCRIPTASE ADVANCED MEDICINE INC (US) 2000-07-20 WO disclosed
EP-1003541-A1 INHIBITORS OF HIV REVERSE TRANSCRIPTASE Advanced Medicine, Inc. (US) 2000-05-31 EP disclosed
WO-1999064048-A1 INHIBITORS OF HIV REVERSE TRANSCRIPTASE ADVANCED MEDICINE, INC. (US) 1999-12-16 WO disclosed
WO-1998040341-A1 PROCESS FOR PREPARATION OF CYCLOPENTENONES IN SUPERCRITICAL FLUIDS HANIL SYNTHETIC FIBER CO., LTD. (KR) 1998-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091269-A1 Synthesis of epothilones and related analogs DHPS, SQLE, FDFT1 MAOA 1284/4885MAOB 1048/4885CA12 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.